तुलना करने के लिए मीट्रिक्स | DMRA | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधDMRAपीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −7.5x | −3.9x | −0.4x | |
PEG अनुपात | 0.12 | 0.00 | 0.00 | |
क़ीमत/बुक | 4.7x | 2.0x | 2.6x | |
क़ीमत / एलटीएम बिक्री | - | 1.1x | 3.0x | |
अपसाइड (विश्लेषक लक्ष्य) | 56.1% | 242.0% | 57.2% | |
उचित मूल्य अपसाइड | अनलॉक करें | 13.2% | 9.6% | अनलॉक करें |
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company’s lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.